$9.10
▼ -2.7% Today
as of Oct 23, 12:15 ET
Last 30 days
Recent Press Releases & News
Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
ATRA earnings at a glance
Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±13.4% on average; after the most recent report on May 12, 2026 it moved +11.7%. ATRA beat the consensus EPS estimate in 2 of its last 2 reported quarters. The share price of $9.10 sits in the middle of its 52-week range.
Overview
52-week range
$3.92
$19
34% of range
Avg surprise (last 2)
+137.7%
Avg reaction (last 2)
+13.4%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.32 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.29 | — | — | -108.3% | +11.7% | earnings |
| Wed Nov 12, 2025 | Sep/2025 | $-0.32 | $-0.83 | +61.5% | — | — | earnings |
| Mon Aug 11, 2025 | Jun/2025 | $0.19 | — | — | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $3.50 | $-3.07 | +214.0% | — | +15.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.93 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.10 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-5.65 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-16.40 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-16.91 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.72 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $630,000 | $516,000 | — | $3M | $18M | $98M | — | $40M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-5M | $-3M | — | $-4M | $3M | $39M | — | $-22M |
| Net income | $-5M | $-4M | — | $-4M | $2M | $38M | — | $-22M |
| EPS (diluted) | $-0.32 | $-0.29 | — | $-0.32 | $0.19 | $3.50 | — | $-2.93 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3M | $8M | $8M | $6M | $17M | $14M | $25M | $46M |
| Inventory | — | — | — | $0 | $0 | $0 | $11M | $14M |
| Total current assets | $14M | $12M | $12M | $18M | $25M | $27M | $65M | $92M |
| Total assets | $21M | $20M | $20M | $30M | $37M | $62M | $109M | $143M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $58M | $57M | $59M | $67M | $72M | $117M | $206M | $233M |
| Total equity | $-37M | $-37M | $-39M | $-37M | $-35M | $-55M | $-97M | $-91M |
Implied volatility — last 90 days
No IV snapshots yet for ATRA.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.
Sector peers
ATRA earnings FAQ
How does ATRA stock usually react to earnings?
Across the last 2 reports the average next-day move was ±13.4%, up 2 times and down 0 times.